Results 21 to 30 of about 416,036 (340)

1-Hydroxy-8-methoxy-anthraquinon reverses cisplatin resistance by inhibiting 6PGD in cancer cells

Open Life Sciences, 2019
Targeting 6-phosphogluconate dehydrogenase (6PGD) can inhibit cancer cell proliferation and tumor growth. However, the relationship between 6PGD and cisplatin resistance still needs further study.
Zhang Huamin, Zhang Haowei, Wang Sihui, Ni Zhihai, Wang Tiejun   +4 more
doaj   +1 more source

Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells [PDF]

, 2010
Inhibition or downregulation of Bcl-2 represents a new therapeutic approach to by-pass chemoresistance in cancer cells. Therefore, we explored the potential of this approach in breast cancer cells.
A Letai, AK Zimmermann, Cagri Bodur, D Moon, D Tian, Dilek Telci, DJ Stewart, Elif Damla Arisan, F Manero, FA Sinicrope, Huveyda Basaga, IJ Enyedy, J An, J Chen, J Skommer, J Yu, JC Reed, JD Lickliter, JI Okani, JL Wang, JL Wang, L Chen, L Ming, L Oliver, M Milella, Ozgur Kutuk, RK Srivastava, SW Lowe, Tugsan Tezil, X Pei, X Wang, XY Pei, Y Ling, Y Su, Z Liu   +34 more
core   +1 more source

Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line

BMC Cancer, 2006
Background Cisplatin is widely used for chemotherapy of head and neck squamous cell carcinoma. However, details of the molecular mechanism responsible for cisplatin resistance are still unclear.
Zhang Ping, Zhang Zhiyuan, Zhou Xiaojian, Qiu Weiliu, Chen Fangan, Chen Wantao   +5 more
doaj   +1 more source

New trends for metal complexes with anticancer activity [PDF]

, 2008
Medicinal inorganic chemistry can exploit the unique properties of metal ions for the design of new drugs. This has, for instance, led to the clinical application of chemotherapeutic agents for cancer treatment, such as cisplatin. The use of cisplatin is,
Ang, Ang, Barnard, Barnes, Bednarski, Bergamo, Bregman, Calderone, Casini, Debreczeni, Dixon, Dyson, Failes, Feazell, Guo, Habtemariam, Hall, Hambley, Hannon, Harris, Heringova, Hillard, Hotze, James, Jung, Komeda, Liu, Lutterman, MacDiarmid, Mackay, Mackay, McNae, Meggers, Milacic, Noor, Oleksi, Orvig, Ott, Pascu, Peacock, Peter J Sadler, Pieter CA Bruijnincx, Reed, Schatzschneider, Schlawe, Scolaro, Smalley, Sun, Thompson, Timerbaev, Urig, Urig, van Zutphen, Wang, Weidt, Yan, Yang   +56 more
core   +1 more source

Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates [PDF]

, 2017
We present the anticancer properties of cis, cis, trans-[Pt(IV)(NH3)2Cl2(OA)2] [Pt(IV)diOA] (OA = octanoato), Pt(IV) derivative of cisplatin containing two OA units appended to the axial positions of a six-coordinate Pt(IV) center.
Brabec, Viktor, Gandin, Valentina, Gibson, Dan, Kasparkova, Jana, Marzano, Cristina, Novohradsky, Vojtech, Osella, Domenico, Pracharova, Jitka, Zanellato, Ilaria   +8 more
core   +1 more source

Time-restricted feeding protects against cisplatin-induced acute kidney injury in mice [PDF]

Kidney Research and Clinical Practice
Background Time-restricted feeding (TRF), devoid of calorie restriction, is acknowledged for promoting metabolic health and mitigating various chronic metabolic diseases.
Kyu Won Jang, Young Suk Kim, Min Jeong Kim, Seo Rin Kim, Dong Won Lee, Soo Bong Lee, Il Young Kim   +6 more
doaj   +1 more source

Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT3 receptor antagonists [PDF]

, 2010
PURPOSE: The ferret cisplatin emesis model has been used for ~30 years and enabled identification of clinically used anti-emetics. We provide an objective assessment of this model including efficacy of 5-HT(3) receptor antagonists to assess its ...
A Fink-Jensen, A Lehmann, A Ozaki, AG King, AH Lau, AL Harris, AM Holmes, AP Florczyk, AP Florczyk, B Costall, B Costall, B Costall, B Costall, B Costall, B Costall, B Lasheras, C Bountra, C. C. Apfel, CJ Gardner, CJ Gardner, CJ Gardner, CL Gooch, D Moher, D Spina, D Tattersall, D Tattersall, DG Altman, DJ Reynolds, DR Gandara, E Blum, E Chevalier, F Roila, FD Tattersall, FD Tattersall, FD Tattersall, GA Higgins, GJ Hollingworth, H Nakayama, H Yamakuni, H Yamakuni, HE Marr, HE Marr, HE Marr, HL Borison, I Angel, I Monkovic, IT Jantunen, J Bermudez, J Hawthorn, J Horn, J Horn, J. A. Rudd, JA Gylys, JA Rudd, JA Rudd, JA Rudd, JA Rudd, JA Rudd, JA Rudd, JA Rudd, JA Rudd, JA Rudd, JA Rudd, JA Rudd, JA Rudd, JA Rudd, JE Schurig, JH Kim, JJ Hale, JJ Hale, JM Barnes, JN Matthews, JW Watson, K Haga, K Haga, L Singh, LE McCarthy, LR Fitzpatrick, LX Cubeddu, M Martin, M Marty, M Minami, M Minami, M Minami, M Ohta, M Tsuchiya, MD Sickle Van, MG Kris, MG Kris, MR Macleod, MR Macleod, MR Macleod, MT Price, N Fukunaka, N Percie du Sert, N Yoshida, N Yoshida, N Yoshida, N Yoshida, N. Percie du Sert, NM Barnes, NM Barnes, NM Rupniak, P Bhandari, P Delagrange, P Pound, P Preziosi, P Ruff, P. L. R. Andrews, PJ Hesketh, PJ Hesketh, PLR Andrews, PLR Andrews, PR Blower, R DerSimonian, R Hargreaves, R Stables, RA Matthews, RC Miller, RD Clark, RD Youssefyeh, RD Youssefyeh, RM Eglen, RM Eglen, RM Eglen, RM Navari, S Bingham, S Gonsalves, S Taniguchi, T Endo, T Endo, T Endo, T Endo, T Endo, T Ito, T Kamato, T Kamato, T Matsui, T Yoshikawa, T Yoshikawa, T Yoshikawa, TM Dando, TS Sam, TS Sam, TS Sam, V Bebarta, WD Miner, WD Miner, WD Miner, Y Kubota, Y Shiroshita, Y Shiroshita, Y Watanabe, YL Liu   +153 more
core   +2 more sources

Targeting HNRNPU to overcome cisplatin resistance in bladder cancer

Molecular Cancer, 2022
Purpose The overall response of cisplatin-based chemotherapy in bladder urothelial carcinoma (BUC) remains unsatisfactory due to the complex pathological subtypes, genomic difference, and drug resistance.
Zhen-duo Shi, Lin Hao, Xiao-xiao Han, Zhuo-Xun Wu, Kun Pang, Yang Dong, Jia-xin Qin, Guang-yue Wang, Xuan-ming Zhang, Tian Xia, Qing Liang, Yan Zhao, Rui Li, Shao-qi Zhang, Jun-hao Zhang, Jian-gang Chen, Gong-cheng Wang, Zhe-Sheng Chen, Cong-hui Han   +18 more
doaj   +1 more source

Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. [PDF]

, 2018
BackgroundThe value of induction chemotherapy (ICT) remains under investigation despite decades of research. New advancements in the field, specifically regarding the induction regimen of choice, have reignited interest in this approach for patients with
Cohen, EEW, Haddad, RI, Hitt, R, Lefebvre, J-L, Posner, M, Schulten, J, Vermorken, JB   +6 more
core   +1 more source

Cisplatin-based chemotherapy of testicular cancer - Two decades after a major breakthrough [PDF]

, 2000
Two decades ago the introduction of cisplatin-based combination chemotherapy has dramatically improved the prognosis of patients with metastatic testicular cancer, At present 3 cycles of cisplatin, etoposide and bleomycin are considered as standard ...
Gerl, Arthur
core   +1 more source